Mark E. Boye

1.2k total citations
40 papers, 851 citations indexed

About

Mark E. Boye is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, Mark E. Boye has authored 40 papers receiving a total of 851 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 9 papers in Economics and Econometrics. Recurrent topics in Mark E. Boye's work include Health Systems, Economic Evaluations, Quality of Life (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Advanced Breast Cancer Therapies (4 papers). Mark E. Boye is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Advanced Breast Cancer Therapies (4 papers). Mark E. Boye collaborates with scholars based in United States, United Kingdom and France. Mark E. Boye's co-authors include Joseph G. Ibrahim, Wei Shen, Jack Mardekian, Mani Lakshminarayanan, Mark P. Jensen, Ming‐Hui Chen, Danjie Zhang, Stacy Hoshaw‐Woodard, Stanley Lemeshow and Diane L. Langkamp and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American Statistical Association and Cancer Research.

In The Last Decade

Mark E. Boye

36 papers receiving 829 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark E. Boye United States	18	169	157	156	141	110	40	851
Paul Celano United States	15	183 1.1×	233 1.5×	84 0.5×	194 1.4×	69 0.6×	24	1.2k
Sarah L. Hulin-Curtis United Kingdom	13	93 0.6×	85 0.5×	76 0.5×	163 1.2×	42 0.4×	22	941
Ulka B. Campbell United States	17	105 0.6×	88 0.6×	129 0.8×	66 0.5×	48 0.4×	31	1.0k
Mugdha Gokhale United States	14	92 0.5×	137 0.9×	79 0.5×	122 0.9×	19 0.2×	31	603
Simona Signoriello Italy	19	216 1.3×	162 1.0×	33 0.2×	324 2.3×	110 1.0×	45	1.3k
Mark W. Donoghoe Australia	16	216 1.3×	115 0.7×	36 0.2×	123 0.9×	47 0.4×	53	1.1k
Roselie A. Bright United States	15	363 2.1×	91 0.6×	25 0.2×	74 0.5×	41 0.4×	25	1.0k
Yusuke Saigusa Japan	16	270 1.6×	202 1.3×	25 0.2×	126 0.9×	44 0.4×	115	1.1k
Michael J. Zoratti Canada	14	68 0.4×	49 0.3×	104 0.7×	89 0.6×	21 0.2×	40	773
Annika Hoyer Germany	18	124 0.7×	29 0.2×	85 0.5×	62 0.4×	33 0.3×	110	1.3k

Countries citing papers authored by Mark E. Boye

Since Specialization

Citations

This map shows the geographic impact of Mark E. Boye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Boye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Boye more than expected).

Fields of papers citing papers by Mark E. Boye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Boye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Boye. The network helps show where Mark E. Boye may publish in the future.

Co-authorship network of co-authors of Mark E. Boye

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Boye. A scholar is included among the top collaborators of Mark E. Boye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Boye. Mark E. Boye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goulding, Rebecca, Gebra Cuyún Carter, Mark E. Boye, et al.. (2020). KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis. Cancer Treatment and Research Communications. 24. 100200–100200. 49 indexed citations

Winfree, Katherine B., Mark E. Boye, Mickaël Basson, et al.. (2017). A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France. ClinicoEconomics and Outcomes Research. Volume 9. 505–518. 5 indexed citations

Camu, F., Alain Borgeat, R. Heylen, et al.. (2016). Parecoxib, propacetamol, and their combination for analgesia after total hip arthroplasty: a randomized non‐inferiority trial. Acta Anaesthesiologica Scandinavica. 61(1). 99–110. 27 indexed citations

Boye, Mark E., Xin Wang, Vichien Srimuninnimit, et al.. (2015). First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial. Clinical Lung Cancer. 17(2). 150–160. 13 indexed citations

Graham, Christopher N., et al.. (2015). Cost-Effectiveness In The Second-Line Treatment Of Non-Small Cell Lung Cancer (Nsclc) In The Us. Value in Health. 18(7). A457–A458. 3 indexed citations

Woods, Beth, Lisa M. Hess, Joseph Treat, et al.. (2015). Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.. Lung Cancer. 89(3). 294–300. 17 indexed citations

Yeaw, Jason, et al.. (2014). Direct Medical Costs for Complications Among Children and Adults with Diabetes in the US Commercial Payer Setting. Applied Health Economics and Health Policy. 12(2). 219–230. 25 indexed citations

Boye, Mark E., et al.. (2014). Can Bundled Payment Improve Quality and Efficiency of Care for Patients with Hip Fractures?. Journal of Aging & Social Policy. 27(1). 1–20. 11 indexed citations

Yeaw, Jason, et al.. (2013). Direct medical costs for complications among adults with type 2 diabetes in a us commercial payer setting. Value in Health. 16(3). A190–A190. 1 indexed citations

10.

Bryden, Peter, et al.. (2013). A Cost-Effectiveness Analysis of Cisplatin Plus Pemetrexed Doublet Induction Treatment Followed by Pemetrexed Maintenance Compared with Bevacizumab Plus Cisplatin Plus Gemcitabine Triplet Induction Treatment Followed by Bevacizumab Maintenance for Non-Squamous NSCLC in Sweden. Value in Health. 16(7). A410–A410. 1 indexed citations

11.

Chawla, Anita, Amit M. Oza, Dave Nellesen, et al.. (2012). PCN148 Review of National Institute for Health and Clinical Excellence (NICE) Recommendations for Anti-Cancer Agents Across Multiple Drug-Indication Combinations. Value in Health. 15(7). A436–A436. 1 indexed citations

12.

Wang, Ping, Wei Shen, & Mark E. Boye. (2012). Joint modeling of longitudinal outcomes and survival using latent growth modeling approach in a mesothelioma trial. Health Services and Outcomes Research Methodology. 12(2-3). 182–199. 21 indexed citations

13.

Voelker, James R., et al.. (2012). PUK17 Economic Benefits of Slowing Progress to End Stage Renal Disease (ESRD) in Patients with Diabetes-Related Chronic Kidney Disease (DKD), Compared with Standard of Care (SOC). Value in Health. 15(4). A155–A155. 1 indexed citations

14.

Querfeld, Christiane, Timothy M. Kuzel, Youn H. Kim, et al.. (2011). Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leukemia & lymphoma. 52(8). 1474–1480. 29 indexed citations

15.

Foster, Talia, Jeffrey D. Miller, Mark E. Boye, et al.. (2011). The economic burden of metastatic breast cancer: A systematic review of literature from developed countries. Cancer Treatment Reviews. 37(6). 405–15. 49 indexed citations

16.

Foster, Talia, Jeffrey D. Miller, Mark E. Boye, & Mason W. Russell. (2009). Economic Burden of Follicular Non-Hodgkinʼs Lymphoma. PharmacoEconomics. 27(8). 657–679. 19 indexed citations

17.

Jensen, Mark P., Jack Mardekian, Mani Lakshminarayanan, & Mark E. Boye. (2007). Validity of 24-h recall ratings of pain severity: Biasing effects of “Peak” and “End” pain. Pain. 137(2). 422–427. 74 indexed citations

18.

Nussmeier, Nancy A., Andrew Whelton, Mark T. Brown, et al.. (2006). Safety and Efficacy of the Cyclooxygenase-2 Inhibitors Parecoxib and Valdecoxib after Noncardiac Surgery. Anesthesiology. 104(3). 518–526. 116 indexed citations

19.

Langkamp, Diane L., Stacy Hoshaw‐Woodard, Mark E. Boye, & Stanley Lemeshow. (2001). Delays in receipt of immunizations in low-birth-weight children: a nationally representative sample.. PubMed. 155(2). 167–72. 68 indexed citations

20.

Kelley, Katherine A., Kristina Secnik, & Mark E. Boye. (2001). An Evaluation of the Pharmacy College Admissions Test as a Tool for Pharmacy College Admissions Committees. American Journal of Pharmaceutical Education. 65(3). 225–230. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact